Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 13, 2011

Otsuka signs psychiatric drug pact with Lundbeck

Japan-based Otsuka Pharmaceutical has signed a deal with Danish pharmaceutical company Lundbeck for the development of psychiatric and neuroscience drugs.

By Liam Stoker

Japan-based Otsuka Pharmaceutical has signed a deal with Danish pharmaceutical company Lundbeck for the development of psychiatric and neuroscience drugs.

The deal covers five medications, including two of Otsuka’s late-stage drugs – a depot formulation of schizophrenia drug Abilify and OPC-34712, currently in Phase III trials for the treatment of schizophrenia and major depressive disorder.

As per the terms of the agreement, Otsuka will receive an upfront payment of $200m from Lundbeck, followed by up to $1.4bn in development and regulatory milestones.

Lundbeck will receive 50% and 20% of European and US sales respectively for the Abilify depot formulation, as well as 50% of sales in Europe and Canada and 45% of US sales of OPC-34712.

Related Companies

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU